Fatal pulmonary hemorrhage after carfilzomib treatment in multiple myeloma. - Suppr | 超能文献

Fatal pulmonary hemorrhage after carfilzomib treatment in multiple myeloma.

作者信息

Kwong Yok-Lam

机构信息

Department of Medicine, Queen Mary Hospital, Pokfulam Road, Pokfulam, Hong Kong,

出版信息

Ann Hematol. 2015 Aug;94(8):1425-6. doi: 10.1007/s00277-015-2392-1. Epub 2015 May 6.

DOI:10.1007/s00277-015-2392-1

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Fatal pulmonary hemorrhage after carfilzomib treatment in multiple myeloma.

Ann Hematol. 2015 Aug;94(8):1425-6. doi: 10.1007/s00277-015-2392-1. Epub 2015 May 6.

2

Fatal pulmonary toxicity due to carfilzomib (Kyprolis™).卡非佐米（凯普拉生™）所致的致命性肺毒性。

J Oncol Pharm Pract. 2016 Oct;22(5):720-4. doi: 10.1177/1078155215588630. Epub 2015 Jun 4.

3

Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.在多发性骨髓瘤治疗中与不可逆蛋白酶体抑制相关的心脏毒性模式。

J Card Fail. 2015 Feb;21(2):138-44. doi: 10.1016/j.cardfail.2014.11.008. Epub 2014 Nov 26.

4

Carfilzomib-associated tumor lysis syndrome.卡非佐米相关的肿瘤溶解综合征。

Pharmacotherapy. 2014 May;34(5):e34-7. doi: 10.1002/phar.1397. Epub 2014 Jan 4.

5

Managing adverse events of multiple myeloma and anti-multiple myeloma treatment: a perspective on carfilzomib.多发性骨髓瘤及抗多发性骨髓瘤治疗的不良事件管理：卡非佐米视角

Oncology (Williston Park). 2013 Dec;27 Suppl 3:2-3.

6

Overview and management of cardiac and pulmonary adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.在接受单药卡非佐米治疗的复发性和/或难治性多发性骨髓瘤患者中，心脏和肺部不良事件的概述和管理。

Oncology (Williston Park). 2013 Dec;27 Suppl 3:24-30.

7

Severe left atrial enlargement due to carfilzomib use in multiple myeloma.多发性骨髓瘤患者使用卡非佐米导致严重左心房扩大。

J Oncol Pharm Pract. 2019 Dec;25(8):2045-2048. doi: 10.1177/1078155218825298. Epub 2019 Jan 12.

8

Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.卡非佐米挽救治疗复发或难治性多发性骨髓瘤患者的疗效和安全性：一项多中心回顾性观察研究。

Br J Haematol. 2016 Jan;172(1):89-96. doi: 10.1111/bjh.13799. Epub 2015 Nov 16.

9

U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.美国食品和药物管理局批准：卡非佐米治疗多发性骨髓瘤。

Clin Cancer Res. 2013 Sep 1;19(17):4559-63. doi: 10.1158/1078-0432.CCR-13-0755. Epub 2013 Jun 17.

10

Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.卡非佐米用于治疗复发和/或难治性多发性骨髓瘤患者。

Future Oncol. 2015;11(15):2121-36. doi: 10.2217/fon.15.123. Epub 2015 Jun 30.

引用本文的文献

1

One CHiP to rule them all? Mechanistic insight into carfilzomib-induced lung injury with neutrophil extracellular trap formation following cellular immunotherapy.一种能统治一切的CHiP？细胞免疫治疗后卡非佐米诱导的伴有中性粒细胞胞外诱捕网形成的肺损伤的机制洞察。

Haematologica. 2025 Jul 1;110(7):1654-1659. doi: 10.3324/haematol.2024.286596. Epub 2025 Feb 13.

2

Bortezomib-Induced Pulmonary Toxicity: A Case Report and Review of Literature.硼替佐米诱导的肺毒性：一例病例报告及文献综述

Case Rep Med. 2018 Nov 25;2018:2913124. doi: 10.1155/2018/2913124. eCollection 2018.